Adaptimmune

The company's core technology is its proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform, which engineers a patient's own T-cells to identify and destroy cancer cells. This approach is designed to overcome the challenges of treating solid tumors, a significant area of unmet medical need where other cell therapies have faced difficulties. In August 2024, Adaptimmune achieved a major milestone with the FDA's accelerated approval for its first product, Tecelra (afami-cel). Tecelra is the first engineered T-cell therapy approved for a solid tumor, specifically for adult patients with unresectable or metastatic synovial sarcoma.

Adaptimmune's business model was historically centered on extensive R&D, funded by collaborations and public markets, but is now transitioning to a commercial focus. Following the approval of Tecelra, the company has been building out its commercial infrastructure, including a network of authorized treatment centers across the U.S. However, in July 2025, Adaptimmune announced an agreement to sell Tecelra and other next-generation cell therapies to US WorldMeds. This strategic shift narrows the company's focus to its internal discovery assets, including therapies targeting PRAME and CD70, with a business model now more dependent on milestone payments and future licensing deals.